The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan

European Journal of Cancer

Volumn 47, Issue 4, 2011, Pages 640-648

  Arnaud, O ^d   Boumendjel, A ^c   Gze, A ^c   Honorat, M ^a,b   Matera, E L ^b   Guitton, J ^a,f   Stein, W D ^e   Bates, S E ^e   Falson, P ^d   Dumontet, C ^a,b   Di Pietro, A ^d   Payen, L ^a,b,f  

^a UNIVERSITÉ LYON 1   (France)

^b INSERM   (France)

^c UNIV GRENOBLE ALPES   (France)

^d University Lyon i   (France)

^e NATIONAL CANCER INSTITUTE   (United States)

^f CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

ABC transporter; ABCG2; Irinotecan; Multidrug resistance; Reversion

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ACRIDONE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; IRINOTECAN; MBLI 87; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOSENSITIZATION; DRUG ACCUMULATION; FEMALE; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 79851507620     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.11.019     Document Type: Article

References (22)

1. S. Shukla, H. Zaher, and A. Hartz Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice Pharm Res 26 2 2009 480 487
2. J.F. Deeken, W.D. Figg, S.E. Bates, and A. Sparreboom Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics Anticancer Drugs 18 2 2007 111 126 (Pubitemid 44967422)
3. W. Loscher, and H. Potschka Blood-brain barrier active efflux transporters: ATP-binding cassette gene family NeuroRx 2 1 2005 86 98 (Pubitemid 40128029)
4. J.W. Polli, K.L. Olson, and J.P. Chism An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016) Drug Metab Dispos 37 2 2009 439 442
5. N.F. Smith, W.D. Figg, and A. Sparreboom Pharmacogenetics of irinotecan metabolism and transport: an update Toxicol In Vitro 20 2 2006 163 175 (Pubitemid 43087700)
6. X.Y. Chu, H. Suzuki, and K. Ueda Active efflux of CPT-11 and its metabolites in human KB-derived cell lines J Pharmacol Exp Ther 288 2 1999 735 741 (Pubitemid 29119689)
7. E. Nicolle, A. Boumendjel, and S. Macalou QSAR analysis and molecular modeling of ABCG2-specific inhibitors Adv Drug Deliv Rev 61 1 2009 34 46
8. T. Hida, S. Ogawa, and J.C. Park Gefitinib for the treatment of non-small-cell lung cancer Expert Rev Anticancer Ther 9 1 2009 17 35
9. C. Lemos, G. Jansen, and G.J. Peters Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors Br J Cancer 98 5 2008 857 862 (Pubitemid 351341599)
10. C.F. Stewart, M. Leggas, and J.D. Schuetz Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice Cancer Res 64 20 2004 7491 7499 (Pubitemid 39372093)
11. N.B. Elkind, Z. Szentpetery, and A. Apati Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) Cancer Res 65 5 2005 1770 1777 (Pubitemid 40478603)
12. M. Leggas, J.C. Panetta, and Y. Zhuang Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo Cancer Res 66 9 2006 4802 4807
13. K. Yanase, S. Tsukahara, and S. Asada Gefitinib reverses breast cancer resistance protein-mediated drug resistance Mol Cancer Ther 3 9 2004 1119 1125 (Pubitemid 39295009)
14. A. Ahmed-Belkacem, A. Pozza, and F. Munoz-Martinez Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2 Cancer Res 65 11 2005 4852 4860 (Pubitemid 40740824)
15. A. Boumendjel, S. Macalou, A. Ahmed-Belkacem, M. Blanc, and A. Di Pietro Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2 Bioorg Med Chem 15 8 2007 2892 2897 (Pubitemid 46402973)
16. Macalou S, Pozza A, Terreux R, Magnard S, Boumendjel A, Pietro AD. Discriminating selective and non-selective inhibitory sites of ABCG2 with acridone derivates. 2010, submitted for publication.
17. R.W. Robey, Y. Honjo, and K. Morisaki Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity Br J Cancer 89 10 2003 1971 1978 (Pubitemid 37533279)
18. L. Choisnard, A. Geze, J.L. Putaux, Y.S. Wong, and D. Wouessidjewe Nanoparticles of beta-cyclodextrin esters obtained by self-assembling of biotransesterified beta-cyclodextrins Biomacromolecules 7 2 2006 515 520
19. A. Gze, L. Choisnard, J.L. Putaux, and D. Wouessidjewe Colloidal systems made of biotransesterified alpha, beta and gamma cyclodextrins grafted with C10 alkyl chains Mater Sci Eng C 29 2009 458 462
20. L. Choisnard, A. Geze, B.G. Yameogo, J.L. Putaux, and D. Wouessidjewe Miscellaneous nanoaggregates made of beta-CD esters synthesised by an enzymatic pathway Int J Pharm 344 1-2 2007 26 32 (Pubitemid 47464829)
21. Y. Zhang, J.P. Bressler, and J. Neal ABCG2/BCRP expression modulates D-luciferin based bioluminescence imaging Cancer Res 67 19 2007 9389 9397 (Pubitemid 47535929)
22. W.D. Stein, J. Yang, S.E. Bates, and T. Fojo Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage Oncologist 13 10 2008 1055 1062